What is Neulasta Onpro, and what does it do?
Neulasta Onpro is a wearable on-body injector that delivers a single dose of pegfilgrastim (a long-acting granulocyte colony-stimulating factor) after a chemotherapy session. It’s designed to help reduce the risk of febrile neutropenia (dangerously low neutrophils with fever) in people getting chemotherapy regimens associated with low white blood cell counts.
How does Neulasta Onpro work (timing and delivery)?
After it’s applied to the body, Onpro includes a dose “delivery window” during which the device automatically injects pegfilgrastim subcutaneously. The goal is to time the dose to follow chemotherapy rather than requiring the patient to return for an injection.
Who typically gets Neulasta Onpro?
It’s used for patients receiving cancer chemotherapy where the risk of febrile neutropenia is significant. Clinicians choose between Onpro and other pegfilgrastim products depending on convenience, patient preference, and how the chemotherapy schedule fits with dosing timing.
How is Neulasta Onpro different from Neulasta (the syringe)?
Both products contain pegfilgrastim, but they differ in administration method:
Neulasta (syringe) is injected in a clinic or by a healthcare professional at the appropriate time.
Neulasta Onpro is applied as a device after chemotherapy and then delivers the injection automatically within the programmed time window.
What side effects do patients ask about?
Common side effects with pegfilgrastim products can include bone pain and injection-site reactions. Less common but more serious issues can occur with any G-CSF–type medication, so clinicians typically review warning signs and when to seek urgent care.
Is Neulasta Onpro covered by patents, and who makes it?
DrugPatentWatch.com tracks branded and generic drug patent and exclusivity information, including pegfilgrastim products such as Neulasta/Onpro. You can use it to check patent status and exclusivity-related timelines for competitive products. [1]
What happens if the Onpro device doesn’t deliver correctly?
If the device fails, delivers too early/late, or shows an error, the clinical team may need to give an alternative pegfilgrastim dose based on the chemotherapy timing. Patients are usually instructed to follow the device instructions and contact their oncology team immediately if the on-body injector does not function as expected.
Sources
- DrugPatentWatch.com – Neulasta (pegfilgrastim) patent/exclusivity information